2025 Annual Report
Filed with SSE · · 225 pages · Chinese
Kexing Biopharm Co., Ltd. on 6ix
Earlier from Kexing Biopharm
- Announcement on Voluntary Disclosure of GB19 Injection Obtaining FDA Clinical Trial Approval for New Drugs
- Announcement on Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
- Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes
- Announcement on Signing Daily Related Party Transaction Agreements
- Announcement on Preliminary Earnings Estimate for 2025
Later from Kexing Biopharm
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of GB10 for Injection
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on the Achievements of Vesting Conditions in the 2nd Vesting Period of the 2024 Restricted Stock Incentive Plan
Follow Kexing Biopharm into a list and get an email when it puts out news.
Follow Kexing Biopharm